CytoReason

As part of CytoReason's growth journey, we are laser-focused on enabling our customers to transform their decision-making from trial-and-error to predictable, with insights from our computational disease models. To help us realize this mission, we’re excited to share that Nicole van Poppel, PhD has recently joined our team as our new Chief Business Officer! Nicole will lead our commercial growth strategy, corporate development, BD & sales, customer success, and customer-facing marketing. She’ll also be establishing our office in Cambridge, MA. With 25+ years of experience working with senior business executives at top life sciences companies, Nicole brings a unique mix of business, science, data and tech expertise. She’s helped many customers transform at scale and realize outcomes with data and technology – in R&D and beyond. Welcome to the the team, Nicole!

English will follow מוזמנים להיפגש איתי מחר בבוסטון לשיחה פתוחה על הבר על מדע, קריירה ומה שבינהם. וכן יש משרות פתוחות אצלינו בצוות בסיטוריזון ששווה לדבר עליהן Hey, Israeli Scholars in Boston! Meet me tomorrow for an informal bar chat on science careers outside academia, the incredible work we are doing in CytoReason, and everything else in between. And yes, we are #hiring Wendnesday December 11th, 6 pm at Miracle of Science Bar + Grill ScienceAbroad CytoReason

Today, we’re grateful for our partners, customers, investors, employees, and everyone who believes in the power of our people and technology to improve the probability of success in drug development. Wishing a Happy Thanksgiving to all who celebrate—thank you for being part of our journey 🙏 ✨

In the recent episode of Biotalk, a podcast by Locust Walk, I took a trip down memory lane, all the way back to the origins of CytoReason. Geoff Meyerson and I talked about some of the pivotal moments in CytoReason's history, for example: -- The “beer on the beach” talk (or how a casual conversation with Shai Shen-Orr inspired us to turn the work of Shai's lab into an AI company working with top pharma enterprises). -- Why we started with immunology (if you've found a way to model immunology, you should be good to go with neurodegenerative and cardiovascular, even with metabolic diseases and oncology). -- My humble advice to entrepreneurs looking to combine AI and life sciences (spoiler – don’t try to reinvent the business model in healthcare – at least three US presidents tried doing it before you. It doesn’t work. There are just too many players, and too much money involved). Thanks Geoff for the opportunity to share CytoReason's story. This was a lot of fun! 👉 Listen to the full episode here: https://lnkd.in/dcjpFGPy

  My guest in the latest Tech on Drugs episode was master drug developer Tom Bumol. Tom, along with his team, spearheaded the development of over 100 drug candidates – including 11 that received approval! He’s held prominent leadership roles at Eli Lilly and the Allen Institute and is a member of CytoReason’s Science Advisory Board. Tom and I talked about a bunch of things, including: -- The process of designing IL-17A-GLP-1 targeting drugs that didn’t just meet expectations – but doubled the efficacy for psoriasis and redefined the standard of care.   -- The huge potential of combination therapies to improve efficacy and minimize resistance by targeting multiple pathways simultaneously.    -- And how AI-driven disease models can help us go beyond incrementalism in drug development. Link to podcast audio and video in comment below 👇

On this episode of Biotalk, Locust Walk's Geoff Meyerson welcomes David H., Chairman, CEO and Co-Founder of CytoReason. David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They explore why molecular data hadn't been used this way before, how CytoReason’s models accelerate drug development, and the evolving role of AI in transforming the industry.    Listen to the episode: https://lnkd.in/ezcAD2_X    #LifeSciences #Biopharma #Biotech #Innovation #Leadership #DrugDevelopment #AIinHealthcare #Pharma #Entrepreneurship #HealthcareInnovation

In the latest episode of Tech on Drugs, CytoReason co-founder Shai Shen-Orr hosts master drug developer Tom Bumol.    Tom's held key leadership positions at Eli Lilly and the Allen Institute. Throughout his career, he developed with his team over 100 molecules – 11 of which received approval! Tom's also a distinguished member of CytoReason's Science Advisory Board. The episode is packed with impactful stories and valuable insights, including: -- Why drugs fail and how human heterogeneity isn’t a hurdle but an opportunity. -- The story of a failed lupus trial that revealed the importance of disease subtypes.  -- An inspiring vision for pharma’s future, where AI, systems biology, and combination therapies drive the shift from trial-and-error to predictability in medicine. Link to podcast audio and video in comment below 👇

The latest Q3 Israeli Tech Review by IVC Data and Insights and LeumiTech highlights the resilience and growth of Israel's high-tech sector, even in a challenging geopolitical landscape. Israeli hi-tech raised a total of $7.4 billion in 330 deals from Q1 to Q3 2024, surpassing 2023's total. No surprise here: generative AI is drawing major investment and driving innovation in the life sciences. We’re proud at CytoReason to be listed here as a top investment in Q3, and to be part of this thriving ecosystem. Read the full report here: https://lnkd.in/eP8NHFpg

At CytoSummit this year we focused on bridging the gaps: •⁠ ⁠Between molecular and clinical data. •⁠ ⁠⁠Between data and insight. •⁠ ⁠⁠And between researchers and decision-makers.  All in the name of improving probability of success for our customers in phase 2 clinical trials. More about CytoReason’s science and technology in the link below 👇